Objective: To determine whether a therapeutic dose of docosahexaenoic acid (DHA), an -3 fatty acid, will slow the course of retinal degeneration in adult patients with retinitis pigmentosa who are also receiving vitamin A.
acid plus vitamin A (DHA+A) group and control plus vitamin A (control + A) group over a 4-year interval among all 221 randomized patients or among the 208 patients who completed all 4 follow-up visits. The mean annual rate of loss of sensitivity for the Humphrey Field Analyzer 30-2 program was 37 dB for the DHA + A group and 38 dB for the control + A group (P = .88). For the Humphrey Field Analyzer 30-2 and 30/60-1 programs combined, the mean annual rates of loss of field sensitivity were 57 dB for the DHA + A group and 60 dB (P = .73) for control + A group. No toxic adverse effects were observed. No significant differences by treatment group assignment were observed within genetic types or within the category of baseline -3 fatty acid intake.
Conclusion:
In patients assigned to receive 15000 IU/d of vitamin A, this randomized trial showed that 1200 mg/d of docosahexaenoic acid supplementation over a 4-year interval did not, on average, slow the course of disease in patients with retinitis pigmentosa.
Arch Ophthalmol. 2004; 122:1297 -1305 R ETINITIS PIGMENTOSA HAS A worldwide prevalence of about 1 in 4000 persons. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Affected patients typically show elevated dark-adaptation thresholds, 11, 12 constricted visual fields, retinal arteriolar attenuation, intraretinal pigment around the midperiphery, and reduced and delayed electroretinograms (ERGs). 13, 14 Histological studies have shown that visual loss occurs owing to degeneration of rod and cone photoreceptors. 15, 16 A prior randomized, controlled trial showed that patients treated with vitamin A palmitate, 15000 IU/d, had, on average, a slower rate of decline of retinal function as monitored by the ERG compared with those not receiving this dose. 17 We and others have found that some patients with retinitis pigmentosa have decreased mean plasma and red blood cell (RBC) docosahexaenoic acid (DHA) concentrations. [18] [19] [20] [21] [22] [23] [24] Rod outer segment membranes contain exceptionally large amounts of polyunsaturated fatty acids, especially DHA. In fact, they compose almost half of the esterified fatty acids in the outer segment phospholipids. [25] [26] [27] Docosahexaenoic acid is a long chain -3 fatty acid found particularly in some fish (eg, salmon and tuna). The RBC DHA levels have been strongly correlated with DHA levels in the retina (r=0.88). 28 The proportion of DHA in outer segment phosphatidylethanolamine (PE) relative to other fatty acids is typically 10-to 15-fold higher than in nonneural tissue such as RBC membranes. 25, 27 The special lipid composition of rod outer segments is thought to be necessary to
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Author affiliations are listed at the end of this article. maintain cellular membrane disc fluidity for the normal functioning of rhodopsin as it changes conformation in the initial stages of phototransduction. 26, [29] [30] [31] [32] [33] Furthermore, it has been proposed that a concentration gradient of DHA normally exists in the subretinal space between the rod outer segments (higher concentration) and the retinal pigment epithelium (lower concentration) and that the release of 11-cis retinal from interphotoreceptor retinoid-binding protein is facilitated when interphotoreceptor retinoid-binding protein is exposed to a sufficient DHA concentration in the subretinal space. [34] [35] [36] [37] Because RBC membrane phospholipid levels are similar in composition to, and change in parallel with, retinal phospholipid levels with dietary manipulation, [38] [39] [40] [41] we evaluated the DHA content of RBC PE in patients with retinitis pigmentosa. We found that RBC PE DHA levels in our patients were significantly lower, on average, than in subjects with normal vision. 24 In an analysis of longitudinal data from participants in our previous trial of vitamin A and/or vitamin E for whom we had RBCs available for analysis at year 3 or 4 of follow-up (n=61), we found that the decline in 30-Hz ERG amplitude in these patients over a 4-year interval was inversely related to the RBC PE DHA concentration (P=.03) for all genetic types combined. These results persisted after controlling for age, sex, genetic type, baseline ERG amplitude, and treatment group assignment in a multiple regression model (P=.05).
The significant positive relationship between RBC PE DHA concentration and the preservation of ERG amplitude, the known role of DHA in maintaining normal photoreceptor function, and the evidence that vitamin A slows the average decline in ERG amplitude in patients with retinitis pigmentosa prompted us to conduct this randomized, controlled clinical trial to determine whether orally administered docosahexaenoic acid can halt or slow the course of the typical forms of retinitis pigmentosa among patients receiving vitamin A (given as retinyl palmitate) therapy.
METHODS

PROTOCOL
We first conducted a pilot study on 35 patients with the typical forms of retinitis pigmentosa who received 600 mg/d (n=9) of docosahexaenoic acid, 1200 mg/d (n = 9) of docosahexaenoic acid, or a placebo control (n=17) over 3 months to determine to what extent these dosages raised the concentration of RBC PE DHA in the short-term. All participants were also treated with 15000 IU/d of vitamin A. Both dosages of docosahexaenoic acid at least doubled the RBC PE DHA concentration and were safely tolerated in this population. We chose the higher dosage of docosahexaenoic acid for this trial assuming that any therapeutic effect would be more readily detected with the higher dosage.
We screened patients with retinitis pigmentosa for eligibility according to ocular, dietary, and medical criteria ( Table 1) . We performed a baseline examination on eligible patients within 8 weeks of the screening examination. At baseline, patients were randomly assigned to 1 of 2 groups-those who received a supplement of 6 capsules per day each containing 500 mg of fatty acids of which 200 mg was docosahexaenoic acid for a total of 1200 mg/d of docosahexaenoic acid or those who received 6 placebo capsules per day containing 500 mg of fatty acids with no docosahexaenoic acid. The docosahexaenoic acid-enriched capsules, provided by Martek Biosciences Corporation, Columbia, Md, contained a vegetable oil from microalgae with ascorbyl palmitate (Ͻ0.001 mg) and tocopherols (Ͻ0.001 mg) as antioxidants. The fatty acid composition was as follows: capric, 0 to 10 mg; lauric, 0 to 30 mg; myristic, 50 to 100 mg; palmitic, 50 to 100 mg; palmitoleic, 0 to 10 mg; stearic, 0 to 10 mg; oleic, 50 to 150 mg; linoleic, 0 to 25 mg; docosahexaenoic, 190 to 210 mg; nervonic, 0 to 10 mg; and others, 0 to 15 mg. The control capsules, also provided by Martek Biosciences Corporation, contained a mixture of 50% corn and 50% soybean oil with ascorbyl palmitate (Ͻ0.001 mg) and tocopherols (Ͻ0.001 mg) as antioxidants. Their fatty acid composition was as follows: palmitic, 45 to 55 mg; stearic, 10 to 20 mg; oleic, 110 to 125 mg; and ␣-linolenic, 15 to 25 mg. Patients were instructed to take 3 capsules in the morning and 3 capsules in the evening. Both the docosahexaenoic acid plus vitamin A (DHA+A)-supplemented group and the control plus vitamin A (control+A) group received 3 g of fatty acids from these capsules; on a 2000-calorie diet this constituted 1.4% of *Elevated final dark-adaptation threshold, retinal arteriolar narrowing, and reduced and delayed ERGs; patients with atypical forms such as paravenous retinitis pigmentosa (RP), sector RP, unilateral RP, Refsum disease, Bardet-Biedl syndrome, and retinitis punctata albescens were excluded. Patients who had RP with profound congenital deafness were also excluded.
†A size V test light was used. ‡Includes glaucoma, uveitis, diabetic retinopathy, posterior subcapsular cataract greater than 11% of the total lens area (ie, equivalent to P3 on the Lens Opacities Classification System III), and pupil diameter after dilation smaller than 6 mm.
§Dark fish was defined as salmon, mackerel, bluefish, or swordfish.
Estimated from reported intake of tuna fish, dark fish, light fish, and shell fish.
calories as fat or an increase of 27 cal/d. All patients were given vitamin A as 15000 IU of retinyl palmitate in tablets (Akorn Ophthalmics, Buffalo Grove, Ill) and instructed to take 1 tablet daily with breakfast. Patients completed a food frequency questionnaire 42, 43 and medical questionnaire at each visit with the aid of a clinical coordinator; they were followed up annually over 4 years ( Table 2) . Plasma and RBC PE DHA levels were monitored as measures of compliance, 44 and serum retinol and retinyl ester levels as well as serum liver function test results were evaluated to help exclude any toxic effects of vitamin A therapy. 45 We used the measurement of static perimetric sensitivities (ie, total point score) with the 30-2 program size V target in the Humphrey Field Analyzer (HFA) (Carl Zeiss Ophthalmic Systems, Inc, Dublin, Calif) as the primary outcome measure. The size V target was used to minimize the number of locations with floor effects (sensitivity Յ0 dB). The FASTPAC test strategy was used to test both central (30-2) and peripheral (30/60-1) visual fields in as short a time as possible. [46] [47] [48] Because the area of the visual field is statistically related to ERG amplitude 49 and because our preliminary data derived from the 30-Hz ERG amplitude, we used the full-field 30-Hz ERG amplitude as a secondary outcome measure. Visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS]) 50 and the total point score to a size V target with the HFA 30-2 and 30/60-1 programs combined were also followed up as secondary outcome measures.
We estimated that 220 patients were needed to provide sufficient power (ie, ␣=.05, ␤=.10) to observe a statistically significant difference (29 dB) between mean change in the DHA+A and control+A groups with respect to HFA 30-2 total point score over a 4-year interval and allowing for 5% attrition. The project was approved by the institutional review boards of the Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, and the study conformed to the Declaration of Helsinki. All patients signed an informed consent form prior to the screening examination and, if eligible, prior to the baseline examination as well. The trial was funded by the National Eye Institute as a single-center study. A Data and Safety Monitoring Committee selected by the National Eye Institute met with the investigators prior to the onset of the study to approve the protocol and annually thereafter in closed session to review the results for both patient safety and efficacy. The study was planned to allow 4 years of follow-up for each patient. The Lan-DeMets ␣-spending approach with an O'Brien-Fleming boundary with 5 looks was prespecified 51 as the stopping rule. However, this stopping rule was just a guideline as the Data and Safety Monitoring Committee needed to consider all information from several measures of efficacy and safety in making informed decisions about stopping the study.
ASSIGNMENT
The procedure for randomization considered the estimated dietary intake and genetic type at the screening examination. A method of block randomization was used within 2 groups of -3 fatty acid intake (above and below the median of 0.16 g/d determined from a food frequency questionnaire administered to patients in our previous therapeutic trial of vitamin A) and 6 genetic types (dominant without known mutation, dominant with known rhodopsin or rhodopsin/peripherin mutation, recessive, X-linked, isolate, or undetermined [eg, adopted]) or 12 strata. Within each stratum, patients were randomized in equal numbers to the DHA+A group and control+A group in blocks of size 4. A separate set of randomization assignments was maintained for each stratum based on a computergenerated set of random numbers that was available only to a programmer who provided assignment information to the data manager (C.W.D.) on a case-by-case basis. Group assignment was implemented by the data manager.
MASKING
All members of the staff in contact with the patients, including the principal investigator (E.L.B.), were masked with regard to each patient's treatment group assignment. Each ocular examination was performed without review of previous records. All serum samples were analyzed without knowledge of treatment group assignment. Patients did not know the contents of the supplement under study or their treatment group assignment and also agreed not to know the course of their retinal degeneration until the end of the study. Treatment group assignments and plasma DHA and RBC PE DHA levels were placed in records separate from that used for ocular examinations as part of masking those in contact with the patients.
DATA ANALYSIS
Outcome data for a given patient for each visit represented the average of test results from both eyes or for a single eye if data for the other eye were unavailable. Visual field data (total point scores) were analyzed separately for the central field (HFA 30-2 program) and for total field (HFA 30-2 and 30/60-1 programs †Completed at each visit and at 6-month intervals between visits by telephone after 6-month supply of capsules was mailed.
combined) when both were available. If an eye became pseudophakic after the baseline visit, visual field data for that eye were analyzed only for those visits prior to cataract surgery. If the total point score for a visual field became zero, the visit at which the zero score was first obtained was included in the analyses but subsequent visits were censored. Slopes and changes from baseline were computed for each patient, and average slopes and mean changes were evaluated for each parameter of ocular function by treatment group. Comparisons by assigned treatment group were also performed within genetic type and within category (ie, above and below the intake of 0.16 g/d) at baseline of dietary -3 fatty acid intake. Longitudinal regression analyses were then performed based on PROC MIXED of SAS version 6.12.
52
The regression models that we used in this clinical trial generally have the following form:
( Although the baseline value is not explicitly specified as a covariate in equation 1, it is implicitly adjusted for because of the correlation between the error terms for the baseline visit and each follow-up visit. In particular, the marginal model in equation 1 can be rewritten in conditional form as follows:
where Corr(u it1 , u it2 ) equals [R/(1+R)]. Equation 2 is a conditional model. Thus, b 2 can be interpreted as the slope in the control+A group (ie, group 2), b 2 +b 3 can be interpreted as the slope in the DHA+A group (ie, group 1), and b 3 is the difference in slope between the DHA+A group and the control+A group after controling for baseline values. 53 Two hundred eight patients were seen for all 4 years of follow-up and the results will focus on these patients. Sensitivity analyses were performed on all 221 patients randomized (1) for all available data and (2) after using multiple imputation methods to account for missing data. †P value for t test comparing 2 groups for continuous variables: P value for 2 for categorical variables. ‡Lower normal level for RBC PE DHA level equals 3.16%; for plasma DHA level, 0.86%. The reference ranges for the levels are as follows: serum retinol, 38 to 100 µg/dL; serum retinyl ester, 34 to 380 nmol/L. Sample sizes for the DHA + A and control + A groups, respectively, were RBC PE DHA, 104 and 100 patients; plasma DHA, 103 and 100; serum retinol, 105 and 103; and retinyl esters, 105 and 103.
§Lower normal level for HFA 30-2 program field (size V target) was 2500 dB; HFA total field (size V target), 4200 dB. The lower normal level for 30-Hz ERG was 50 µV; lower normal level for 0.5-Hz ERG, 350 µV. The lower normal level for ETDRS visual acuity was 60 letters; 51 letters indicated a Snellen visual acuity of 20/30; sample sizes for DHA + A and control + A groups, respectively, were: HFA 30-2 program, 103 and 102 patients; HFA total field, 102 and 102; 30-Hz ERG, 101 and 100; 0.5-Hz ERG, 61 and 53; and EDTRS visual acuity, 105 and 103.
Values designated as mean log e ± SE. Geometric means for ERG amplitudes are given in parentheses. 
PARTICIPANT FLOW AND FOLLOW-UP
From May 13, 1996 , to September 26, 1997, we examined 456 patients from across the United States to identify 221 patients (1 per family) with retinitis pigmentosa who met the preset list of eligibility criteria. Two hundred eight of these patients completed all 4 annual follow-up visits. Baseline characteristics of these 208 patients for factors used in the stratification of the randomization (ie, genetic type and dietary -3 fatty acid intake) are given in Table 3 by assigned treatment group. Also given is baseline information concerning the distribution of demographic factors, ocular function, and laboratory measures of DHA and retinol concentrations. Ninety-seven percent of the eligible patients had intraretinal bone spicule pigmentation around the midperipheral fundus. Eleven percent of patients reported partial hearing loss. Six percent of the study population were minorities. With the exception of RBC PE DHA levels, no significant differences in any of the above patient characteristics were noted between the DHA+A and control+A groups. Fifty percent of patients in the DHA+A group and 64% of patients in the control+A group had cataracts in at least 1 eye at baseline (P=.05).
SAFETY AND COMPLIANCE
Capsule counts indicated that 92% of the docosahexaenoic acid capsules, 92% of the control capsules, and 94% of the vitamin A tablets were consumed over all 4 years. Similar results were seen with returned monthly calendars. One patient in the control + A group diagnosed as having breast cancer just before her year 4 visit died 4 months after the year 4 visit. No other patient reported the development of cancer to us during the study. No patient experienced a complete loss of vision in an eye over the course of the study. Furthermore, there was no evidence of systemic illness or a toxic effect that was attributable to the study capsules or to vitamin A during the course of this study based on complete blood cell counts, liver function assessments, patient responses to a symptom questionnaire, and on the serum retinol and serum retinyl ester levels. Two patients were examined by the consulting internist, 1 for gastrointestinal distress thought subsequently to be due to anxiety and the other for discoloration of the skin that proved subsequently to be related to Cushing syndrome.
Prior to treatment, the DHA + A and control + A groups showed comparable levels of plasma DHA (Table  3) . At follow-up, mean ± SE plasma DHA percentages (mean of all follow-up measurements) of total plasma fatty acids were 5.12% ± 0.12% and 1.61% ± 0.07% for the DHA+A group vs the control+A group, respectively; mean change from baseline for the DHA + A group was significantly different from the mean change from baseline for the control+A group (PϽ.001). By year 1 the mean plasma DHA percentage of total fatty acids was 3-fold higher in the DHA+A group than in the control + A group and remained at that level for the 4 years of follow-up; no significant increase in plasma DHA percentage was noted in the control+ A group.
Prior to treatment, the mean±SE RBC PE DHA percentage of total RBC PE fatty acids was significantly higher in the DHA+A group (4.77%±0.18%) vs the control+A group (4.27%±0.14%) (P=.03) ( Table 3 ). At year 1 of follow-up the mean±SE RBC PE DHA percentages of total RBC PE fatty acids for the DHA+A group vs the control+A group were 12.62%±0.28% and 4.90%±0.18%; at year 4 the mean RBC PE DHA percentages of total fatty acids were 12.83%±0.05% and 4.66%±0.18% for the 2 groups, respectively. Averaging years 1 and 4, the mean±SE change from baseline for the DHA+A group (7.95±0.30) and mean change from baseline for the control+A group (0.51±0.11) were both significantly different from zero (PϽ.001) and were significantly different from each other (PϽ.001). The RBC PE DHA values ranged from 2% to 18% of the total RBC PE fatty acids prior to treatment in both groups and at follow-up from 3% to 17% of the total RBC PE fatty acids in the DHA + A group and from 2% to 10% in the control+A group (Figure 1) . Table 4 lists serum triglyceride and cholesterol levels at screening and year 4 for the 2 groups. The difference in slopes for the 2 groups was significant for the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol. screening and baseline values) did not reveal statistically significant differences between the 2 treatment groups for any of these 4 measures. 30-Hz ERG amplitude, and of ETDRS visual acuity for the DHA+A group vs the control + A group among the 208 patients followed up for each of 4 annual visits. No significant differences in rates of change were observed between these 2 groups. Both groups lost, on average, about 37 to 38 dB per year to the HFA 30-2 program condition and 57 to 60 dB to the HFA 30-2 and 30/60-1 programs combined. These total point score declines correspond to losses of approximately 0.5 dB and 0.4 dB per year, respectively, for an average location in the visual field. Over 4 years, analysis of 30-Hz ERGs showed that the mean annual rates of decline of remaining function were 9.92% in the DHA + A group and 10.49% in the control + A group, which was not statistically significantly different (P = .64). These analyses were also performed on all available data, including patients with partial follow-up, but with missing values left as missing and after using multiple imputation methods to account for missing data among patients with incomplete followup. No substantive differences were noted between results obtained with these additional approaches compared with those in Table 5 . A similar analysis as in Table  5 was performed for 0.5-Hz ERG amplitudes based on the 55% of patients with quantifiable responses; mean rate of decline for the DHA + A group (11.8%) was not significantly different from that for the control+A group (10.4%) (P =.54).
ANALYSIS OF OUTCOME MEASURES
We also performed randomized comparisons by genetic type and by dietary intake of -3 fatty acids. No significant differences by treatment group assignment were observed for either the primary or the secondary outcome measures within the dominant, recessive, Xlinked, or isolate forms of retinitis pigmentosa or within the category of baseline dietary -3 fatty acid intake (above and below intake of 0.16 g/d) (data not shown).
COMMENT
The present trial shows that in adult patients with retinitis pigmentosa, assigned to 15 000 IU/d of vitamin A, a daily supplement of 1200 mg of docosahexaenoic acid over a 4-year interval does not, on average, slow the course of retinal degeneration. Both the DHA+A and control+A groups lost 37 to 38 dB of visual field sensitivity to the HFA 30-2 program (size V target), 58 to 60 dB of visual field sensitivity to the HFA 30-2 and 30/60-1 programs combined (size V target), 10% of remaining 30-Hz cone ERG amplitude, and 0.7 letter of ETDRS visual acuity per year. No significant toxic adverse effects were noted over the course of this trial both for docosahexaenoic acid or vitamin A supplementation. Similarly, docosahexaenoic acid supplementation (400 mg/d) was associated with no identifiable safety risks over 4 years among 23 males with X-linked retinitis pigmentosa. 55 No significant treatment effect was noted within any of the genetic types. Serum triglyceride levels increased by about 25% in the control+A group as described previously. 45 In both groups the high-density lipoprotein cholesterol level increased and the low-density lipoprotein cholesterol level decreased or remained stable. On balance, changes in these values would not increase the risk for heart disease.
Good separation as monitored by mean RBC PE DHA levels was achieved between the DHA+A group vs the control+A group. The DHA+A group had a mean RBC PE DHA level 2-to 3-fold greater than the control+A group at 1 year and 4 years. At follow-up, averaging years 1 and 4, the mean RBC PE DHA level increased by 0.51% from baseline for the control+A group (significantly different from zero, PϽ.001) and increased 7.95% for the DHA+A group. How this RBC PE DHA change in the control+A group may have influenced their results and, thus, the comparison of results to the DHA+A group is unclear.
The lack of a significant difference in rate of loss of ocular function between the DHA + A and control + A groups precludes any general recommendation of DHA supplementation for patients with retinitis pigmentosa receiving vitamin A. Further investigation of these data from this trial or other trials may help to clarify whether any subgroups of patients with retinitis pigmentosa will benefit from a combination of docosahexaenoic acid plus vitamin A supplementation.
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